For the leverage to be more in the future, we need to have more unlocking in the US pipeline, which is what most analysts are also saying.

Buy Cipla Ltd. at a price target of Rs 603. The US ramp up as well as benefits from cost control initiatives should drive earnings.

“Assuming 10-15% market share and price discount of 25-30%, gSeretide could be a USD25-35m annual sales opportunity for Cipla,” said HSBC.

"Considering the number of patients in India, we should be in a position to serve all of them. I do not think consideration should be on a ...

Tipped as a possible successor to CEO Andrew Witty, Dingemans spoke to ET in Mumbai during his recent trip on plans for India.

India’s third-largest drug maker Cipla has reshuffled its senior management team, the third time it’s doing so in as many years.

As per the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries

They have added Cipla to their GEMs Super 15 portfolio list. It ranks in the top 50 EM companies that are most defensive.

Asthma patients may breathe easier as GSK has halved the prices of its Seretide inhaler in India to match that of Cipla’s competing brand S...

Shares of Cipla fell nearly 3 per cent intraday after rivals Mylan launched first generic version of anti-asthma drug Seretide.

The approval is for 25mcg+50mcg/dose, 25 mcg + 125 mcg/dose and 25 mcg + 250 mcg/dose formulation strengths, the company said in a statemen...

Nomura has set a price target of Rs 569 for the stock, implying 9% potential downside from the Thursday’s closing price of Rs 622.

Dealers are recommending to accumulate the stock as funds are extremely bullish on the counter.

The maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.

Analysts at Emkay Global Financial Services are of the view that the launch will have a strong positive impact on the company’s margins.

Macquarie has downgraded the ratings of Tata Steel to ‘Underperform’ with a target price of Rs 306. Tata Steel, on a P/B adjusted for goodw...

Cipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...